Haws Bryn T, Cui Wei, Persons Diane L, Zhang Da
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS.
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS.
Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):679-683. doi: 10.1016/j.clml.2016.08.017. Epub 2016 Aug 20.
Only a few studies have investigated the presence of increased MYC gene copy number (ICN) as a prognostic indicator in patients with diffuse large B-cell lymphoma (DLBCL), and the results have been variable. We compared overall survival in patients with ICN to MYC-negative patients and investigated the prognostic significance of increased MYC gene copy number.
Two groups, those with MYC ICN (n = 33) and those with no MYC aberrations (n = 43), identified by fluorescence in-situ hybridization DNA probes for the MYC region at 8q24, were compared for survival (1-9 years), MYC immunohistochemical (IHC) protein expression, and treatment protocol. Comparison of cases of DLBCL with MYC ICN to those with no MYC aberration demonstrated no significant difference in survival (P = .58). Additionally, no difference in survival was found between patients with increased MYC protein expression (IHC MYC ≥ 40%) compared to those with IHC MYC < 40% (P = .5).
Comparison of Ki-67 proliferation rates, stratified into low and high groups, did not achieve statistical significance (P = .67). Patients with MYC ICN showed a slightly increased MYC protein expression (P > .05). Importantly, the majority of patients in both groups (79% of patients with ICN and 81% of patients with no MYC aberrations) were treated with rituximab-based therapies.
No significant difference in survival was found between patients with DLBCL with MYC ICN and patients with no MYC aberrations (P = .58).
仅有少数研究调查了MYC基因拷贝数增加（ICN）作为弥漫性大B细胞淋巴瘤（DLBCL）患者预后指标的情况，结果存在差异。我们比较了MYC基因拷贝数增加的患者与MYC阴性患者的总生存期，并研究了MYC基因拷贝数增加的预后意义。
通过针对8q24区域MYC的荧光原位杂交DNA探针，将两组患者进行比较，一组为MYC ICN患者（n = 33），另一组为无MYC异常患者（n = 43），比较其生存期（1 - 9年）、MYC免疫组化（IHC）蛋白表达及治疗方案。比较DLBCL中MYC ICN患者与无MYC异常患者的病例，发现生存期无显著差异（P = 0.58）。此外，与IHC MYC < 40%的患者相比，IHC MYC≥40%（MYC蛋白表达增加）的患者生存期也无差异（P = 0.5）。
将Ki-67增殖率分为低、高两组进行比较，未达到统计学意义（P = 0.67）。MYC ICN患者的MYC蛋白表达略有增加（P > 0.05）。重要的是，两组中的大多数患者（ICN患者中的79%和无MYC异常患者中的81%）均接受了基于利妥昔单抗的治疗。
DLBCL中MYC ICN患者与无MYC异常患者的生存期无显著差异（P = 0.58）。
